Peter Wehrwein, Managing Editor

The price tag of $2.9 million is typical of a new wave of gene therapies. The manufacturer, BioMarin Pharmaceutical, is offering arrangements that will link the price paid by payers to how well patients respond to the treatment.

Sarah K. Emond, M.P.P., will take over as president and CEO of the Institute for Clinical and Economic Review (ICER) next year. Steve Pearson, M.D.,M.Sc., founded the organization, which has become the leading cost-effectiveness assessment organization of pharmaceuticals in the U.S.

The Sandoz's and Boehinger Ingelheim's Humira biosimilars will join Amgen's Amjevita on the formulary of UnitedHealth Group's PBM. Cyltezo may have a marketing edge because of its interchangeability designation.

Legislation designed to smooth the path to exemptions from step therapy has been incorporated into the Pharmacy Benefit Reform Act, one of several bills targeting pharmacy benefit managers that is making legislative headway in the Senate.

Briana Contreras, an editor with Managed Healthcare Executive, and Peter Wehrwein, managing editor of MHE, got to chatting with the newest editorial advisory board member, Jeffrey Casberg, who is vice president of Clinical Pharmacy at IPD Analytics.

Research results reported by Cornell researchers show price increases when neonatal intensive care units (NICUs) affiliated with practice management companies, but quality indicators largely hold steady.

The drugs must have full “traditional” FDA approval and patients need to be enrolled in a registry that collects post-approval data efficacy and safety when the drugs are used in clinical practice.

The head of a gastroenterologist group criticizes the company for having a "slapdash approach."

Vanderbilt’s Stacie Dusetzina and colleagues explain how the ‘copay adjustment’ programs work in this week’s JAMA Internal Medicine and also shed light on third strategy used by insurers and pharmaceutical benefit managers, the alternative payment program.

The Biden-McCarthy leaves $5 billion intact for coronavirus vaccine and treatment research, according to multiple media reports.

The company said 21% of its Medicare Advantage members are in plans with 2023 ratings of 4.0 or above, a steep decline from the 2023 star ratings.

The announcement mentions the growth in Medicare Advantage during his five-year tenure.

Results reported in JAMA comparing Black and White populations show a narrowing and then leveling off of excess mortality and potential years of life lost before the difference widened again in 2020.

Medicaid redetermination may result in a favorable payer mix for some providers if people switch to ACA and employer-based coverage that has higher payer rates. But that is a pretty big if.

Coverage of Ozempic, Wegovy; eliminating hepatitis C, $100,000 bonsues for nurses

Audits and following prevention “bundles” were among the steps infection control leaders took at the Sparrow Health System long-term acute-care hospital in Lansing, Michigan.

Oxygen supplementation may be necessary, especially for newborns born prematurely. But the oxygen free radicals associated with high levels can be harmful, causing conditions such as retinopathy of prematurity, which can result in blindness. A review article discusses how researchers and clinicians have found the right balance between high and low oxygen supplementation for newborns.

Over 7,000 people attended the meeting in Las Vegas this week.

Ed Paiewonsky, Director, Medical Outcomes Science Liaison at Alnylam Pharmaceuticals, discussed results of the Alnylam Rare Disease Trend report at this year's Asembia Specialty Pharmacy Summit.

But payers may be putting undue emphasis on interchangeability, said a panelist at session on biosimilars at the 2023 Asembia Specialty Pharmacy Summit.

Adam Fein, Ph.D., talked about some surprising trends in specialty pharmacy and healthcare at the 2023 Asembia Specialty Pharmacy Summit. The number of specialty pharmacy locations may be peaking. And that "gross-to-net bubble" in drug prices that Fein has written about so much — well, it may be shrinking.

“It was like, we’re going to take off your head, we are going to come after you,” said Seema Verma, the Centers for Medicare and Medicaid Administrator in the Trump administration, during an on-stage interview at the 2023 Asembia Specialty Pharmacy Summit.

A relatively small number of cell and gene therapies have become a clinical reality. But now the specialty pharmacy industry, and healthcare more generally, is bracing for a wave of cell and gene therapies that will force change and adaption. And, yes, the new therapies will be extremely costly.

A little-known provision of the Inflation Reduction Act will allow people with Part D coverage to "smooth out" their annual out-of-pocket costs as an average payment over months.

Daybue (trofinetide) is the first treatment for Rett syndrome. The pivotal trial for treatment for a lifelong condition was only 12 weeks long.

More PBM legislation, Medicaid work requirements are a hot topic, low-value care's main culprits

Biden's bid for re-election, AHIP takes on Pharma and the digital health's equity problems

The Senate Finance Committee released a framework for legislation this week, and the leaders of the “big three” PBMs are scheduled to be witnesses at another committee's hearing about insulin prices on May 10.

CDC researchers estimate an almost 50% decrease in those with uncovered costs associated with HIV preexposure prophylaxis (PrEP). More people who are PrEP eligible have insurance and the cost of PrEP has declined.

Medicare Advantage plans have been associated with increased screening rates. But managed care tactics and narrow networks may be a disadvantage for people needing care.